Barbara Sahakian

Last updated

Barbara Jacquelyn Sahakian
Spouse Trevor Robbins [1]
Awards Fellow of the Academy of Medical Sciences (2004)
F C Donders Chair of Psychopharmacology (2005)
Alfred Deakin Innovation Lecture (2008)
University of Pennsylvania Distinguished International Scholar Award (2009)
ICGP Senior Investigator Award (2010)
Doctor of Science (2015)
Fellow of the British Academy (2017)
Scientific career
Institutions University of Cambridge
Clare Hall, Cambridge
Barbara Sahakian's voice
from the BBC programme The Life Scientific , 29 May 2012. [2]

Barbara Jacquelyn Sahakian, FBA , FMedSci is professor of clinical neuropsychology at the department of psychiatry and Medical Research Council (MRC)/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge. She is also an honorary clinical psychologist at Addenbrooke's Hospital, Cambridge. [3] She has an international reputation in the fields of cognitive psychopharmacology, neuroethics, neuropsychology, neuropsychiatry and neuroimaging. [4] [5] [6]

Contents

Sahakian is a fellow of Clare Hall, Cambridge. [7] She is currently president of the International Neuroethics Society (INS), of which she is a founder member. [8] She is past president of the British Association for Psychopharmacology (BAP), having served as president from 2012 to 2014. [9]

Education

Sahakian completed her PhD in psychopharmacology at Darwin College, Cambridge in the department of psychology at the University of Cambridge. [10] Following this, Sahakian studied for a Diploma in Clinical Psychology and became a Chartered Psychologist. [11]

Career

Sahakian is best known for her work on cognitive enhancement using pharmacological treatments, early detection of Alzheimer's disease, cognition and depression and neuroethics. Sahakian's research is aimed at understanding the neural basis of cognitive, emotional and behavioural dysfunction to develop more effective pharmacological and psychological treatments. The focus of her lab is on early detection of neuropsychiatric disorders, differential diagnosis and proof of concept studies using cognitive enhancing drugs and cognitive training. [9]

In her research, Sahakian uses techniques such as psychopharmacological, neuropsychological and neuroimaging (fMRI and PET). Key research areas for her group are Alzheimer's disease, Attention Deficit Hyperactivity Disorder (ADHD), Obsessive Compulsive Disorder (OCD), substance abuse, depression and mania. [4] [5]

In 2007, Sahakian raised concerns regarding the ethics of using drugs intended to help dementia and Alzheimer's patients to instead enhance cognitive function in healthy people. [12] [13] In May 2014, Sahakian published an article on the subject of achieving brain health for a flourishing society within the next decade. [14] In this article, she included a list of experts from a range of areas, including neuroscience, innovation and technology. Sahakian was asked to write this article for Sir John Beddington, Chief Scientific Adviser to the UK Government. [15]

Sahakian has published over 400 papers [5] covering these topics in scientific journals, including many publications in the prestigious scientific and medical journals Science , [16] Nature , [17] Nature Neuroscience , [18] The Lancet , [19] and the British Medical Journal . [20] [21] She is an associate editor of Psychological Medicine . [22] The ISI Web of Science database credits her with a Hirsch (h) Index of 100. [23]

Sahakian is co-author of 'Bad Moves. How decision making goes wrong and the ethics of smart drugs', published by Oxford University Press in 2013. [24] She is also co-editor of 'The Oxford Handbook of Neuroethics', published in 2011 by Oxford University Press. [25]

In addition to her Presidencies of the BAP and INS, Sahakian is also on the council of the International College of Neuropsychopharmacology (CINP) [26] and on the European College of Neuropsychopharmacology (ECNP) Review Board. [27] She is also a London Imperial Affiliated Professor [28] and a Distinguished Research fellow at the Oxford Uehiro Centre for Practical Ethics. [29] Previously, Sahakian has been a member of the MRC Neurosciences and Mental Health Board (2006–2010) and a member of the Society for Neuroscience (SfN) Committee on Women in Neuroscience. [9] Recently, a Royal Institution article named Barbara Sahakian amongst the top women in science. [30]

Inventions

Sahakian's research uses neuropsychological tests, such as the Cambridge Neuropsychological Test Automated Battery (CANTAB) tests, which she co-invented in the 1980s. [31] CANTAB is now used at over 700 research institutes worldwide and is backed by over 1,200 peer-review articles. [32] Sahakian serves as a Senior Consultant to Cambridge Cognition, a spin-out of the University of Cambridge. Cambridge Cognition now provides CANTAB. [33]

The CANTAB PAL touchscreen test, which assesses visual memory and new learning, received the highest rating of world-leading 4* grade from the Research Excellence Framework (REF) 2014. [34] [35] Following this award, CANTAB and CANTAB PAL were highlighted in the Medical Schools Council 'Health of the Nation' 2015 publication, which described CANTAB as a boost to the UK economy. [36]

Neuroscience and mental health policy

Sahakian is a lead on many high-impact international neuroscience and mental health policy reports, [37] including the National Institute of Mental Health (NIMH) funded report on Grand Challenges in Global Mental Health [38] and the UK Government Foresight Project on Mental Capital and Wellbeing in 2008. [39] The latter project emphasised good brain health and wellbeing throughout the life course and highlighted important concepts, such as cognitive reserve and resilience to stress. [40]

Sahakian recently presented on neuroscience and mental health policy at the World Economic Forum (WEF) 2014 in Davos, Switzerland. She is a Member of the WEF Global Agenda Council on Brain Research. [41]

Press

Sahakian frequently engages the public in science, appearing on programmes such as BBC Newsnight, [42] and on both The Life Scientific [2] and the Today Programme [43] on BBC Radio 4. She has also taken part in numerous newspaper interviews, such as The Sunday Times [44] and Forbes Online. [45] In 2012, Sahakian contributed to the catalogue and appeared in a video for the Wellcome Trust Superhuman Exhibition. [46] In May 2014, she took part in a Reddit Ask Me Anything (AMA), fielding questions on a range of subjects, such as depression and cognitive enhancing drugs. [47] In July 2014, Sahakian dispelled the myth that humans only use 10% of their brains in regard to the plot of the film Lucy . [48] In March 2015, she advised on the 'You have been upgraded' event at the Science Museum in London, which featured demonstrations by members of her Laboratory. [49] In the context of presentations on neuroscience, brain health, cognitive enhancement and neuropsychiatric disorders, she has frequently stated the importance of understanding brain health and disease. [50] [51]

Honours and awards

Since 2004, Sahakian has been a Fellow of the Academy of Medical Sciences. [52] She is also associated with the Human Brain Project. [53] Sahakian is also a Member of the International Expert Jury for the 2017 Else Kröner-Fresenius-Stiftung Prize. [54]

Sahakian was he was appointed to the F C Donders Chair of Psychopharmacology at the University of Utrecht in 2005 and the Distinguished International Scholar Award at the University of Pennsylvania in 2009. In 2010, she received the International College of Geriatric Psychoneuropharmacology (ICGP) Senior Investigator Award. [9] In 2008, Sahakian gave the Alfred Deakin Innovation Lecture in Melbourne, Australia. [55]

In 2015, Sahakian was awarded a Doctor of Science degree from the University of Cambridge, [56] which is the highest degree awarded by the university for distinguished research in science. [57]

In July 2017, Sahakian was elected a Fellow of the British Academy (FBA), the United Kingdom's national academy for the humanities and social sciences. [58]

Selected publications

Related Research Articles

<span class="mw-page-title-main">Neuroscience</span> Scientific study of the nervous system

Neuroscience is the scientific study of the nervous system, its functions and disorders. It is a multidisciplinary science that combines physiology, anatomy, molecular biology, developmental biology, cytology, psychology, physics, computer science, chemistry, medicine, statistics, and mathematical modeling to understand the fundamental and emergent properties of neurons, glia and neural circuits. The understanding of the biological basis of learning, memory, behavior, perception, and consciousness has been described by Eric Kandel as the "epic challenge" of the biological sciences.

<span class="mw-page-title-main">Cognitive neuroscience</span> Scientific field

Cognitive neuroscience is the scientific field that is concerned with the study of the biological processes and aspects that underlie cognition, with a specific focus on the neural connections in the brain which are involved in mental processes. It addresses the questions of how cognitive activities are affected or controlled by neural circuits in the brain. Cognitive neuroscience is a branch of both neuroscience and psychology, overlapping with disciplines such as behavioral neuroscience, cognitive psychology, physiological psychology and affective neuroscience. Cognitive neuroscience relies upon theories in cognitive science coupled with evidence from neurobiology, and computational modeling.

<span class="mw-page-title-main">Nootropic</span> Drug, supplement, or other substance that improves cognitive function

Nootropics are numerous natural, semi-synthetic and synthetic molecules that claim to improve cognitive functions.

In philosophy and neuroscience, neuroethics is the study of both the ethics of neuroscience and the neuroscience of ethics. The ethics of neuroscience concerns the ethical, legal and social impact of neuroscience, including the ways in which neurotechnology can be used to predict or alter human behavior and "the implications of our mechanistic understanding of brain function for society... integrating neuroscientific knowledge with ethical and social thought".

Cognitive liberty, or the "right to mental self-determination", is the freedom of an individual to control their own mental processes, cognition, and consciousness. It has been argued to be both an extension of, and the principle underlying, the right to freedom of thought. Though a relatively recently defined concept, many theorists see cognitive liberty as being of increasing importance as technological advances in neuroscience allow for an ever-expanding ability to directly influence consciousness. Cognitive liberty is not a recognized right in any international human rights treaties, but has gained a limited level of recognition in the United States, and is argued to be the principle underlying a number of recognized rights.

Martha Julia Farah is a cognitive neuroscience researcher at the University of Pennsylvania. She has worked on an unusually wide range of topics; the citation for her lifetime achievement award from the Association for Psychological Science states that “Her studies on the topics of mental imagery, face recognition, semantic memory, reading, attention, and executive functioning have become classics in the field.”

<span class="mw-page-title-main">Music psychology</span> Branch of both psychology and musicology

Music psychology, or the psychology of music, may be regarded as a branch of both psychology and musicology. It aims to explain and understand musical behaviour and experience, including the processes through which music is perceived, created, responded to, and incorporated into everyday life. Modern music psychology is primarily empirical; its knowledge tends to advance on the basis of interpretations of data collected by systematic observation of and interaction with human participants. Music psychology is a field of research with practical relevance for many areas, including music performance, composition, education, criticism, and therapy, as well as investigations of human attitude, skill, performance, intelligence, creativity, and social behavior.

<span class="mw-page-title-main">Dan J. Stein</span>

Dan Joseph Stein is a South African psychiatrist who is a professor and Chair of the Dept of Psychiatry and Mental Health at the University of Cape Town, and Director of the South African MRC Unit on Risk & Resilience in Mental Disorders. Stein was the Director of UCT's early Brain and Behaviour Initiative, and was the inaugural Scientific Director of UCT's later Neuroscience Institute. He has also been a visiting professor at Mount Sinai School of Medicine in the United States, and at Aarhus University in Denmark.

<span class="mw-page-title-main">Neurolaw</span>

Neurolaw is a field of interdisciplinary study that explores the effects of discoveries in neuroscience on legal rules and standards. Drawing from neuroscience, philosophy, social psychology, cognitive neuroscience, and criminology, neurolaw practitioners seek to address not only the descriptive and predictive issues of how neuroscience is and will be used in the legal system, but also the normative issues of how neuroscience should and should not be used.

Trevor William RobbinsCBE FRS FMedSci is a professor of cognitive neuroscience and the former Head of the Department of Psychology at the University of Cambridge. Robbins interests are in the fields of cognitive neuroscience, behavioural neuroscience and psychopharmacology.

The Cambridge Neuropsychological Test Automated Battery (CANTAB), originally developed at the University of Cambridge in the 1980s but now provided in a commercial capacity by Cambridge Cognition, is a computer-based cognitive assessment system consisting of a battery of neuropsychological tests, administered to subjects using a touch screen computer. The CANTAB tests were co-invented by Professor Trevor Robbins and Professor Barbara Sahakian. The 25 tests in CANTAB examine various areas of cognitive function, including:

<span class="mw-page-title-main">National Core for Neuroethics</span>

The National Core for Neuroethics at the University of British Columbia was established in August 2007, with support from the Canadian Institutes of Health Research, the Institute of Mental Health and Addiction, the Canada Foundation for Innovation, the British Columbia Knowledge Development Fund, the Canada Research Chairs program, the UBC Brain Research Centre and the UBC Institute of Mental Health. Co-founded by Judy Illes and Peter Reiner, the Core studies neuroethics, with particular focus on ethics in neurodegenerative disease and regenerative medicine, international and cross-cultural challenges in brain research, neuroimaging and ethics, the neuroethics of enhancement, and personalized medicine.

Karen D. Davis is a neuroscience professor at the University of Toronto, and is the head of Division of Brain, Imaging & Behaviour, Krembil Research Institute at the University Health Network. Davis was inducted into the Johns Hopkins Society of Scholars in 2009, the Canadian Academy of Health Sciences in 2018 and the Royal Society of Canada in 2020 and is currently the president of the Canadian Pain Society.

<span class="mw-page-title-main">Adrian Owen</span>

Adrian Mark Owen is a British neuroscientist and best-selling author. He is best known for his 2006 discovery, published in the journal Science, showing that some patients thought to be in a persistent vegetative state are in fact fully aware and able to communicate with the outside world using functional magnetic resonance imaging (fMRI). In the 2019 New Year Honours List, Owen was made an Officer of the Most Excellent Order of the British Empire (OBE) for services to scientific research.

Neuroenhancement or cognitive enhancement refers to the targeted enhancement and extension of cognitive and affective abilities based on an understanding of their underlying neurobiology in healthy persons who do not have any mental illness and outcomes in experimental research. As such, it can be thought of as an umbrella term that encompasses pharmacological and non-pharmacological methods of improving neurological functionality, especially interventions designed to improve human form or functioning beyond what is necessary to sustain or restore good health, as well as the overarching ethico-legal discourse that accompanies these aims and practices.

Usha Claire Goswami is a researcher and professor of Cognitive Developmental Neuroscience at the University of Cambridge, a Fellow of St. John's College, Cambridge, and the director of the Centre for Neuroscience in Education, Downing Site. She obtained her Ph.D. in developmental psychology from the University of Oxford before becoming a professor of cognitive developmental psychology at the University College London. Goswami's work is primarily in educational neuroscience with major focuses on reading development and developmental dyslexia.

The International Neuroethics Society (INS) is a professional organization that studies the social, legal, ethical, and policy implications of advances in neuroscience. Its mission is to encourage and inspire research and dialogue on the responsible use of advances in brain science. The current INS President is Joseph J. Fins, MD.

Mark J. Millan is a neuroscientist specialising in the study and improved treatment of disorders of brain. He was the Director of Pharmacological Innovation for the Central Nervous System (CNS) at the Institute de Recherché de Servier (IDRS) in Paris, France. He is also the Secretary of the European College of Neuropsychopharmacology. Currently he is a Visiting Professor in the School of Psychology and Neuroscience at Glasgow University. Born in Edinburgh, Scotland, he is the son of former Scottish Labour Party Leader and European Commissioner, Bruce Millan, studied at Cambridge University and then spent ten years at the Max Planck Institut fur Psychiatrie, Munich, before moving to Paris.

Adriana Galván is an American psychologist and expert on adolescent brain development. She is a professor of psychology at the University of California, Los Angeles (UCLA) where she directs the Developmental Neuroscience laboratory. She was appointed the Jeffrey Wenzel Term Chair in Behavioral Neuroscience and the Dean of Undergraduate Education at UCLA.

Roshan Cools is a Professor of Cognitive Neuropsychiatry at Radboud University Nijmegen. She is interested in the motivational and cognitive control of human behaviour and how it is impacted by neuromodulation. She was elected to the Royal Netherlands Academy of Arts and Sciences in 2018.

References

  1. ↑ "ROBBINS, Prof. Trevor Robbins". Oxford University Press. A & C Black. 2014. Retrieved 17 April 2015.
  2. 1 2 "Barbara Sahakian". The Life Scientific. 29 May 2012. BBC Radio 4 . Retrieved 18 January 2014.
  3. ↑ "Profile: Barbara Sahakian". World Economic Forum. Retrieved 20 June 2014.
  4. 1 2 "Profile: Barbara Sahakian". Cambridge Neuroscience. Retrieved 20 June 2014.
  5. 1 2 3 Barbara Sahakian publications indexed by Microsoft Academic
  6. ↑ "BBC Radio 4 – The Life Scientific, Barbara Sahakian" . Retrieved 4 December 2012.
  7. ↑ "Fellows of Clare Hall". Clare Hall, University of Cambridge. Archived from the original on 14 July 2014. Retrieved 20 June 2014.
  8. ↑ "Professor Barbara Sahakian elected President of the International Neuroethics Society". Cambridge Neuroscience. 12 August 2013. Retrieved 19 August 2014.
  9. 1 2 3 4 "Professor Barbara Sahakian - BAP Officer Profile". The British Association for Psychopharmacology. Retrieved 7 September 2014.
  10. ↑ Sahakian, Barbara (1977). The effects of isolation on the unconditional behaviour and response to drugs in rats (PhD thesis). University of Cambridge.
  11. ↑ "Barbara Sahakian: Profile". The Oxford Centre for Neuroethics. Archived from the original on 17 April 2015. Retrieved 17 April 2015.
  12. ↑ Sahakian, Barbara. "Decision Making & the Ethics of "Smart Drugs"". The Global Herald. 24 Hour Trading Ltd. Archived from the original on 8 June 2013. Retrieved 5 June 2013.
  13. ↑ Sahakian, B.; Morein-Zamir, S. (2007). Sahakian, B. J.; Morein-Zamir, S. (eds.). "Professor's little helper". Nature. 450 (7173): 1157–1159. Bibcode:2007Natur.450.1157S. doi:10.1038/4501157a. PMID   18097378. S2CID   2051062.
  14. ↑ Sahakian, Barbara J. (June 2014). "What do experts think we should do to achieve brain health?". Neuroscience & Biobehavioral Reviews. 43: 240–258. doi:10.1016/j.neubiorev.2014.04.002. PMID   24742821. S2CID   13786765.
  15. ↑ "What do experts think we should do to achieve brain health? Press Release". Department of Psychiatry, University of Cambridge. Archived from the original on 9 June 2014. Retrieved 20 June 2014.
  16. ↑ Sahakian, B. J.; Morein-Zamir, S. (2009). "Neuroscientists Need Neuroethics Teaching". Science. 325 (5937): 147. doi:10.1126/science.325_147a. PMID   19589983.
  17. ↑ Insel, T. R.; Sahakian, B. J.; Voon, V.; Nye, J.; Brown, V. J.; Altevogt, B. M.; Bullmore, E. T.; Goodwin, G. M.; Howard, R. J.; Kupfer, D. J.; Malloch, G.; Marston, H. M.; Nutt, D. J.; Robbins, T. W.; Stahl, S.; Tricklebank, M. D.; Williams, J. H. (2012). "Drug research: A plan for mental illness". Nature. 483 (7389): 269. Bibcode:2012Natur.483..269I. doi: 10.1038/483269a . PMID   22422245.
  18. ↑ Aron, A. R.; Fletcher, P. C.; Bullmore, E. T.; Sahakian, B. J.; Robbins, T. W. (2003). "Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans". Nature Neuroscience. 6 (2): 115–116. doi:10.1038/nn1003. PMID   12536210. S2CID   10096947.
  19. ↑ Sahakian, B. J.; Malloch, G.; Kennard, C. (2010). "A UK strategy for mental health and wellbeing". The Lancet. 375 (9729): 1854–5. doi:10.1016/S0140-6736(10)60817-3. PMID   20511002. S2CID   205959009.
  20. ↑ Sugden, C.; Aggarwal, R.; Housden, C.; Sahakian, B. J.; Darzi, A. (2010). "Pharmacological enhancement of performance in doctors". BMJ. 340: c2542. doi:10.1136/bmj.c2542. PMID   20483930. S2CID   13763309.
  21. ↑ Orrell, M.; Sahakian, B. (1995). "Education and dementia". BMJ. 310 (6985): 951–952. doi:10.1136/bmj.310.6985.951. PMC   2549351 . PMID   7728017.
  22. ↑ "Psychological Medicine: Editorial Board". Cambridge University Press. Retrieved 26 September 2014.
  23. ↑ "Barbara Sahakian – Citation Report". Web of Science. Retrieved 20 June 2014.
  24. ↑ "Bad Moves Book Details". Oxford University Press. Retrieved 20 June 2014.
  25. ↑ "Oxford Handbook of Neuroethics". Oxford University Press. Retrieved 20 June 2014.
  26. ↑ "CINP Executive Committee & Council 2014 - 2016". CINP. Archived from the original on 19 June 2009. Retrieved 25 March 2015.
  27. ↑ "Review Board". ECNP. Archived from the original on 3 November 2013. Retrieved 20 June 2014.
  28. ↑ "Barbara Sahakian at the WEF". Cambridge Neuroscience. Retrieved 20 June 2014.
  29. ↑ "Barbara Sahakian's Profile". University of Oxford Practical Ethics. Archived from the original on 15 July 2014. Retrieved 20 June 2014.
  30. ↑ Cardew, Gail (8 March 2014). "Top 10 women in science – an impossible task?". The Royal Institution. Archived from the original on 18 September 2020. Retrieved 13 August 2014.
  31. ↑ Sahakian, B. J.; Morris, R. G.; Evenden, J. L.; Heald, A.; Levy, R.; Philpot, M.; Robbins, T. W. (1988). "A Comparative Study of Visuospatial Memory and Learning in Alzheimer-Type Dementia and Parkinson's Disease". Brain. 111 (3): 695–718. doi:10.1093/brain/111.3.695. PMID   3382917.
  32. ↑ "Overview of CANTAB". Cambridge Cognition. Retrieved 20 June 2014.
  33. ↑ "Science Team". Cambridge Cognition. Retrieved 20 June 2014.
  34. ↑ "REF Impact Case Study - CANTAB-PAL". Research Excellence Framework. Retrieved 11 February 2015.
  35. ↑ "World-leading UK medical research showcased in new publication". Medical Schools Council. 29 January 2015. Archived from the original on 11 February 2015. Retrieved 11 February 2015.
  36. ↑ "Health of the Nation" (PDF). Medical Schools Council. 2015. Archived from the original (PDF) on 11 February 2015. Retrieved 11 February 2015.
  37. ↑ "Barbara Sahakian Q&A". Cambridge Science Festival. Retrieved 20 June 2014.
  38. ↑ Collins, P. Y.; Patel, V.; Joestl, S. S.; March, D.; Insel, T. R.; Daar, A. S.; Bordin, I. A.; Costello, E. J.; Durkin, M.; Fairburn, C.; Glass, R. I.; Hall, W.; Huang, Y.; Hyman, S. E.; Jamison, K.; Kaaya, S.; Kapur, S.; Kleinman, A.; Ogunniyi, A.; Otero-Ojeda, A.; Poo, M.; Ravindranath, V.; Sahakian, B. J.; Saxena, S.; Singer, P. A.; Stein, D. J.; Anderson, W.; Dhansay, M. A.; Ewart, W; Phillips, A.; Shurin, S.; Walport, M. (2011). "Grand challenges in global mental health". Nature. 475 (7354): 27–30. doi:10.1038/475027a. PMC   3173804 . PMID   21734685.
  39. ↑ "Mental Capital and Wellbeing Foresight Report". UK Government. Retrieved 20 June 2014.
  40. ↑ Beddington, J.; Cooper, C. L.; Field, J.; Goswami, U.; Huppert, F. A.; Jenkins, R.; Jones, H. S.; Kirkwood, T. B.; Sahakian, B. J.; Thomas, S. M. (2008). "The mental wealth of nations" (PDF). Nature. 455 (7216): 1057–60. Bibcode:2008Natur.455.1057B. doi:10.1038/4551057a. PMID   18948946. S2CID   205040827.
  41. ↑ "Cambridge Neuroscience". Barbara Sahakian at the WEF in Davos 2014. Retrieved 20 June 2014.
  42. ↑ Watts, Susan (9 November 2011). "Do cognitive-enhancing drugs work?". BBC News. Retrieved 20 June 2014.
  43. ↑ "Brain Stimulation Report". BBC Today. 26 January 2012.
  44. ↑ Martin, Minette (3 January 2010). "It's a no-brainer – bring on the pills that will make us smarter". The Sunday Times . The Sunday Times. Archived from the original on 14 July 2014. Retrieved 20 June 2014.
  45. ↑ Kotler, Stephen (14 May 2012). "Training The Brain of an Entrepreneur". Forbes. Retrieved 20 June 2014.
  46. ↑ "Superhuman Collection". Wellcome Trust. Archived from the original on 4 July 2014. Retrieved 10 July 2014.
  47. ↑ Sahakian, Barbara (30 May 2014). "From lost memories to brain drugs, a neuroscientist explains". The Conversation. Retrieved 20 June 2014.
  48. ↑ Blackburn, Ralph (20 July 2014). "The underused brain? It's all in the mind: Film-makers' much-loved idea that we only use 10 per cent of our grey cells is a fiction". The Independent. Retrieved 10 November 2014.
  49. ↑ "Brain training at the Science Museum". Cambridge Neuroscience. 8 April 2015. Retrieved 6 May 2015.
  50. ↑ Sahakian, Barbara (15 August 2013). "Burden of brain disorders ignored by government". The Conversation. Retrieved 10 July 2014.
  51. ↑ Sahakian, Barbara (16 May 2014). "Five brain challenges we can overcome in the next decade". The Conversation. Retrieved 10 July 2014.
  52. ↑ "Barbara Sahakian – Profile". Academy of Medical Sciences. Archived from the original on 1 August 2016. Retrieved 20 June 2014.
  53. ↑ "Principal Investigators". Human Brain Project. Archived from the original on 3 July 2014. Retrieved 20 June 2014.
  54. ↑ "The 2017 Else Kröner Fresenius Preis für Medizinische Forschung". Else Kröner-Fresenius-Stiftung. Archived from the original on 25 September 2015. Retrieved 24 September 2015.
  55. ↑ Miller, Nick (6 June 2008). "'Smart drugs' need smarter risk-handling". The Age. Retrieved 15 September 2014.
  56. ↑ "Congregation of the Regent House on 21 March 2015". Cambridge University Reporter. No. 6381. 25 March 2015. Retrieved 31 March 2015.
  57. ↑ "Information for candidates for the ScD Degree". University of Cambridge. 30 August 2012. Retrieved 31 March 2015.
  58. ↑ "Elections to the British Academy celebrate the diversity of UK research". British Academy. 2 July 2017. Retrieved 29 July 2017.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.